Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILA-C5253 | Cynomolgus | Cynomolgus IL-2 R beta Protein, Fc Tag |  |
|
|
| ILA-C82E3 | Cynomolgus | Biotinylated Cynomolgus IL-2 R beta Protein, His,Avitag™ (MALS verified) |  |
|
|
| ILB-C52H9 | Cynomolgus | Cynomolgus IL-2 R beta / CD122 Protein, His Tag (MALS verified) |  |
|
|
| ILB-M5253 | Mouse | Mouse IL-2 R beta / CD122 Protein, Fc Tag |  |
|
|
| ILA-C52H5 | Canine | Canine IL-2 R beta Protein, His Tag |  |
|
|
| ILA-M52H5 | Mouse | Mouse IL-2 R beta Protein, His Tag |  |
|
|
| ILB-H82E3 | Human | Biotinylated Human IL-2 R beta / CD122 Protein, His,Avitag™ |  |
|
|
| ILB-H5253 | Human | Human IL-2 R beta / CD122 Protein, Fc Tag (MALS & SPR verified) |  |
|
|
| CD2-H5221 | Human | Human IL-2 R beta / CD122 Protein, His Tag (SPR verified) |  |
|
|
Cynomolgus IL-2 R beta, His Tag (Cat. No. ILB-C52H9) immobilized on CM5 Chip can bind Cynomolgus IL-2, His Tag (Cat. No. IL2-C5249) with an affinity constant of 377 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Bempegaldesleukin | BMS-986321; ONO-7911; NKTR-214 | Phase 3 Clinical | Nektar Therapeutics | Coronavirus Disease 2019 (COVID-19); Melanoma; Neoplasm Metastasis; Lymphoma; Glioma; Sarcoma, Ewing; Brain Neoplasms; Neuroblastoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Solid tumours; Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Leukemia; Medulloblastoma; Rhabdomyosarcoma; Head and Neck Neoplasms; Ependymoma; Skin Melanoma | Details |
| GI-101 | SIM-323; SIM323; SIM0323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Vaginal Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Vulvar Neoplasms; Sarcoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma | Details |
| Pegenzileukin | THOR-707; SAR-444245 | Phase 2 Clinical | Synthorx Inc | Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Esophageal adenocarcinoma; Oropharyngeal Neoplasms; Intestinal Neoplasms; Multiple Myeloma; Mesothelioma; Lymphoma, Large B-Cell, Diffuse; Skin Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms | Details |
| IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
| LTC-004 | LTC004; LTC-004 | Phase 2 Clinical | Leto Laboratories Co Ltd | Solid tumours; Pancreatic Neoplasms; Neoplasms; Sarcoma; Colorectal Neoplasms | Details |
| IAP-0971 | IAP-0971 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| TransCon IL-2 β/γ | Phase 2 Clinical | Ascendis Pharma A/S | Ovarian Neoplasms; Solid tumours; Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| MDNA-11 | MDNA-11; MDNA11 | Phase 2 Clinical | Medicenna Therapeutics Corp | Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Skin Neoplasms; Skin Melanoma; Carcinoma, Ovarian Epithelial; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Ovarian Neoplasms; Solid tumours | Details |
| Simlukafusp alfa | FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma | Details |
| BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Communicable Diseases; Neoplasm Metastasis | Details |
| STK-009 | STK-009 | Phase 1 Clinical | Synthekine Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| FB-102 | FB-102; FB102 | Phase 1 Clinical | Forte Biosciences Inc | Alopecia Areata; Graft vs Host Disease; Vitiligo; Malabsorption Syndromes | Details |
| NL-201 (Neoleukin Therapeutics) | NL-201 | Phase 1 Clinical | Neoleukin Therapeutics Inc | Solid tumours | Details |
| Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z
